Abstract:Background: P38α is a ubiquitous protein kinase, which plays diverse roles in cancers. Surprisingly, P38α functions vary markedly in different cancers (e.g., cancer suppressor vs cancer promoter). However, there is no report on the expression of P38α, the family's most important member, in pancreatic ductal adenocarcinoma (PDAC) and its association with clinicoathological parameters and patients' prognosis. Materials and methods: We retrospectively analyzed 152 patients who underwent surgery and were pathologically diagnosed with PDAC from September 2013 to September 2015. We used immunohistochemistry to detect P38α expression in tumor and adjacent normal tissues. The significance of the association between P38α and clinicopathological parameters was evaluated using the χ² test and t tests. The Kaplan-Meier method was used to assess the association between P38α expression and preoperative carbohydrate antigen 19-9 (CA19-9) levels and patients' overall survival. The Cox regression model was used to analyze the association between clinicopathological parameters, P38α and preoperative CA19-9 levels, and prognosis. Statistical significance was defined as P < 0.05. Results: P38α was expressed in 63.16% tumor tissues of PDAC, which was significantly higher compared with the adjacent normal tissues (26.32%, P < 0.001). High expression of P38α was associated with patients' histological grade (P = 0.013), lymphatic metastasis (P = 0.025) and TNM stage (P = 0.048). The median survival time of the P38α-high group was 9.2 months, which was shorter compared with that of the P38α-low group (17.3 months, P = 0.011). The median survival time of the CA19-9 > 43.63 group was 11.1 months shorter than that of the CA19-9 < 43.63 group (24.8 months, P < 0.001). The Cox regression model revealed that age (P = 0.003), lymphatic invasion (P = 0.015), TNM stage (P = 0.003), histological grade (P < 0.001), preoperative CA19-9 (P = 0.049), and P38α expression (P = 0.008) were statistically significant independent risk factors affecting prognosis. Specifically, overall survival was 28.4 months in the P38α-low and CA19-9 < 43.63 groups, 16.3 months in the P38α-high or CA19-9 > 43.63 groups, and 9.7 months in the P38α-high and CA19-9 > 43.63 groups (P < 0.001). Conclusions: High expression of P38α was significantly associated with histological grade, lymphatic metastasis, TNM stage and prognosis in patients with PDAC. P38α and preoperative CA19-9 levels were independent risk factors affecting the prognosis of PDAC patients. High expression of p38α and preoperative carbohydrate antigen 19-9 indicate poor prognosis in patients with PDAC.

Expression of Ki67 and p53 and their Relationship with the Survival Time of High-Dose Hypofractionated Radiotherapy in Pancreatic Cancer

The relationship of expression of p53,p21,Ki-67 and VEGF and bladder cancer stage,grade and prognosis

[A Study of the Gene Encoding Ki-67 Antigen in Human Pancreatic Cancer Using Non-Radioactive in Situ Hybridization and Immunohistochemistry].

Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors

[Relationship Between the Protein Expression of P53, C-Erbb-2, Vascular Endothelial Growth Factor and CD44 and the Survival Rates of Stage II( Colorectal Cancer Patients Without Radiochemotherapy after Radical Resection].

The Relationship between Regional Lymph Node Metastases and Expression of P53 and Ki67 in Pancrestic Carcinoma and its Prognostic Significance

Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray.

High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma

Sequential High-Intensity Focused Ultrasound Treatment Combined with Chemotherapy for Inoperable Pancreatic Cancer: a Retrospective Analysis for Prognostic Factors and Survival Outcomes

Recurrence and Survival Prediction Models for Receiving Preoperative Chemotherapy Pancreatic Ductal Adenocarcinoma Cancer: A Single-center Retrospective Research

Effect of KRAS Mutations and P53 Expression on the Postoperative Prognosis of Patients with Colorectal Cancer.

Prognostic Value of Programmed Cell Death Protein 1 Expression on CD8+ T Lymphocytes in Pancreatic Cancer

Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.

The predictive value of immunohistochemical markers for the prognosis of primary peritoneal malignancies

Association Between Ki67 Expression and Therapeutic Outcome in Colon Cancer.

Expression and significance of Her-2,P53 and Ki-67 in colorectal cancer

High p53 Protein Level Is a Negative Prognostic Marker for Pancreatic Adenocarcinoma

Serum HSP70 and VEGF levels are effective predictive factors of chemoradiosensitivity and prognosis of pancreatic cancer patients

Treatment and Prognostic Factors Affecting on Pancreatic Cancer Survival

Prognostic Value of Clinicopathological Characteristics in Patients with Pancreatic Cancer.

The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature.